<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><description>药事纵横是一个由多位制药精英联合创办的媒体平台，旨在分享与传递药品研发、生产和注册中所涉及的技术、经验和情报，欢迎关注和投稿！投稿请发442015666@qq.com</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 26 Jan 2021 07:43:03 +0800</pubDate><image><url>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</url><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>分析方法验证的统计学评价：检测限，定量限和性线</title><link>https://mp.weixin.qq.com/s/zuYQknSxEfRdQvLY5bT5cg</link><description></description><content:encoded><![CDATA[分析方法验证的统计学评价：检测限，定量限和性线]]></content:encoded><pubDate>Mon, 25 Jan 2021 23:18:33 +0800</pubDate></item><item><title>石药集团副总裁党群专访|前药技术在发现改良型新药中的应用-缩短研发周期，降低研发成本</title><link>https://mp.weixin.qq.com/s/7iry1DtkMeKL1EmwOARmRA</link><description></description><content:encoded><![CDATA[石药集团副总裁党群专访|前药技术在发现改良型新药中的应用-缩短研发周期，降低研发成本]]></content:encoded><pubDate>Mon, 25 Jan 2021 23:18:33 +0800</pubDate></item><item><title>干粉吸入剂那些不得不说的事</title><link>https://mp.weixin.qq.com/s/uWb_73gE16-odumW4UTIsw</link><description></description><content:encoded><![CDATA[干粉吸入剂那些不得不说的事]]></content:encoded><pubDate>Mon, 25 Jan 2021 23:18:33 +0800</pubDate></item><item><title>未知杂质定性之液质图谱中分子量的解析原则</title><link>https://mp.weixin.qq.com/s/_lUDJUYVgw5ZMIhMgWDo8Q</link><description></description><content:encoded><![CDATA[未知杂质定性之液质图谱中分子量的解析原则]]></content:encoded><pubDate>Mon, 25 Jan 2021 23:18:33 +0800</pubDate></item><item><title>分析方法验证的统计学评价：准确度与精密度</title><link>https://mp.weixin.qq.com/s/XLicziLlpzP5xHWUF8W3tA</link><description></description><content:encoded><![CDATA[分析方法验证的统计学评价：准确度与精密度]]></content:encoded><pubDate>Sun, 24 Jan 2021 20:44:07 +0800</pubDate></item><item><title>默克寄予厚望的PD-L1/TGFβ双抗，肺癌三期临床试验失败</title><link>https://mp.weixin.qq.com/s/DV9LSDi4Bgup9u6tbLz4Og</link><description></description><content:encoded><![CDATA[默克寄予厚望的PD-L1/TGFβ双抗，肺癌三期临床试验失败]]></content:encoded><pubDate>Sun, 24 Jan 2021 20:44:07 +0800</pubDate></item><item><title>药用玻璃包装容器影响药品质量的相关问题浅析</title><link>https://mp.weixin.qq.com/s/1CYmFKNpOPfjf3_X9sCfXQ</link><description></description><content:encoded><![CDATA[药用玻璃包装容器影响药品质量的相关问题浅析]]></content:encoded><pubDate>Sun, 24 Jan 2021 20:44:07 +0800</pubDate></item><item><title>药事纵横广告投放须知</title><link>https://mp.weixin.qq.com/s/d0CrX_EyBT2u3MPcuuu0MQ</link><description></description><content:encoded><![CDATA[药事纵横广告投放须知]]></content:encoded><pubDate>Sun, 24 Jan 2021 20:44:07 +0800</pubDate></item><item><title>PROTAC技术详梳理-1-总结篇</title><link>https://mp.weixin.qq.com/s/svBaqlfGs6IMgG87N27WrQ</link><description></description><content:encoded><![CDATA[PROTAC技术详梳理-1-总结篇]]></content:encoded><pubDate>Sun, 24 Jan 2021 09:41:24 +0800</pubDate></item><item><title>新公众号“药海书香”，期待各位大佬的关注</title><link>https://mp.weixin.qq.com/s/giFWxnBrWqhOHCa-vmqmgg</link><description></description><content:encoded><![CDATA[新公众号“药海书香”，期待各位大佬的关注]]></content:encoded><pubDate>Sun, 24 Jan 2021 09:41:24 +0800</pubDate></item><item><title>每月一次的长效纳米晶制剂获得FDA批准用于艾滋病治疗</title><link>https://mp.weixin.qq.com/s/XrHIZpMm1KKWtD4V1H6TXw</link><description></description><content:encoded><![CDATA[每月一次的长效纳米晶制剂获得FDA批准用于艾滋病治疗]]></content:encoded><pubDate>Sat, 23 Jan 2021 13:12:46 +0800</pubDate></item><item><title>新公众号“药海书香”，期待各位大佬的关注</title><link>https://mp.weixin.qq.com/s/RNwalYTeaIdogiSTatTCyg</link><description></description><content:encoded><![CDATA[新公众号“药海书香”，期待各位大佬的关注]]></content:encoded><pubDate>Sat, 23 Jan 2021 13:12:46 +0800</pubDate></item><item><title>壳聚糖在药物制剂中的应用</title><link>https://mp.weixin.qq.com/s/qIebmjRyO9SjRU1ctBu-TQ</link><description></description><content:encoded><![CDATA[壳聚糖在药物制剂中的应用]]></content:encoded><pubDate>Fri, 22 Jan 2021 08:08:36 +0800</pubDate></item><item><title>2021年第一响：FDA批准新型抗心衰药​Vericiguat</title><link>https://mp.weixin.qq.com/s/0rmTphlRRR7iAcmyHjw44g</link><description></description><content:encoded><![CDATA[2021年第一响：FDA批准新型抗心衰药​Vericiguat]]></content:encoded><pubDate>Fri, 22 Jan 2021 08:08:36 +0800</pubDate></item><item><title>仿制药竞争依然激烈，不会布局，必将淘汰</title><link>https://mp.weixin.qq.com/s/meqiu91Vb0QJPLVL2p3kHQ</link><description></description><content:encoded><![CDATA[仿制药竞争依然激烈，不会布局，必将淘汰]]></content:encoded><pubDate>Fri, 22 Jan 2021 08:08:36 +0800</pubDate></item><item><title>读罗氏发家史：全球最大生物制药与诊断巨头是如何炼成的</title><link>https://mp.weixin.qq.com/s/qfqGAzks5NSDZnmeXzHM4g</link><description></description><content:encoded><![CDATA[读罗氏发家史：全球最大生物制药与诊断巨头是如何炼成的]]></content:encoded><pubDate>Wed, 20 Jan 2021 19:57:50 +0800</pubDate></item><item><title>干法制粒机有奖问卷调研，点击参与</title><link>https://mp.weixin.qq.com/s/eL7g3hfXX0y7IbURwWOGyw</link><description></description><content:encoded><![CDATA[干法制粒机有奖问卷调研，点击参与]]></content:encoded><pubDate>Wed, 20 Jan 2021 19:57:50 +0800</pubDate></item><item><title>万变不离其宗的药品价格管理</title><link>https://mp.weixin.qq.com/s/lgDbCxqv4B7GuQ_m7I1Tjg</link><description></description><content:encoded><![CDATA[万变不离其宗的药品价格管理]]></content:encoded><pubDate>Wed, 20 Jan 2021 19:57:50 +0800</pubDate></item><item><title>杂质的控制点和控制策略</title><link>https://mp.weixin.qq.com/s/kUiTcO0KFY_vttPrvd47xA</link><description></description><content:encoded><![CDATA[杂质的控制点和控制策略]]></content:encoded><pubDate>Wed, 20 Jan 2021 19:57:50 +0800</pubDate></item><item><title>基于Xgboost算法降低质量成本</title><link>https://mp.weixin.qq.com/s/V5wz4do5HFBOv_D4yb10sg</link><description></description><content:encoded><![CDATA[基于Xgboost算法降低质量成本]]></content:encoded><pubDate>Wed, 20 Jan 2021 10:12:43 +0800</pubDate></item></channel></rss>